PerioTrap Pharmaceuticals awarded 800.000,00 EUR public funding for developing new drugs and delivery systems for treating periodontitis

Infectious diseases are often treated with broadband antibiotics that act against a great range of bacteria. The systemic application of antibiotics always has a negative impact of the person’s body, frequently noticeable by side effect on the gastrointestinal tract. In cases like periodontitis, where keystone pathogens disrupt the homoeostasis of a well balanced  and diverse microbiota, the eradication of the majority of bacteria poses an even a greater risk. A recurrence of the pathology is almost inevitable if the oral microbiota stays in dysbiosis as pathogens are more likely to colonize when beneficial effects of the commensals are missing. In order to deliver targeted treatments against the disease-causing pathogens, PerioTrap has now been awarded two public grants by the German Federal State of Saxony-Anhalt, AMEPA and ParoStop, with money from the European Regional Development Fund (ERDF). The received funding will be used to progress PerioTrap’s inhibitors and the according delivery technology that ensures a sustained drug release at the site of infection into regulatory stages.